TY - JOUR
T1 - The unperturbed picture
T2 - Label-free real-time optical monitoring of cells and extracellular vesicles for therapy
AU - Marjanovic, Marina
AU - Boppart, Stephen A.
N1 - The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Drs. Marjanovic and Boppart receive partial financial salary and research support from GSK, through the Center for Optical Molecular Imaging. Dr. Boppart also has disclosed and patented intellectual property through the University of Illinois at Urbana–Champaign related to nonlinear optical imaging.
We would like to thank the members of the Biophotonics Imaging Laboratory and the Center for Optical Molecular Imaging at the Beckman Institute for Advanced Science and Technology on the campus of the University of Illinois Urbana–Champaign. In particular, we would like to thank our colleagues and collaborators from GSK, including Dr. Steve Hood and Dr. Aneesh Alex, for their inspiration and support of using advanced optical imaging in the pharmaceutical industry. We would also like to thank Rishyashring Raman Iyer, Alexander Ho, and Jindou Shi for their help on figure illustrations and valuable discussion during the preparation of this paper. This work was supported in part by grants from NIH (R01CA213149 and R01CA241618). Additional information can be found at http://biophotonics.illinois.edu.
We would like to thank the members of the Biophotonics Imaging Laboratory and the Center for Optical Molecular Imaging at the Beckman Institute for Advanced Science and Technology on the campus of the University of Illinois Urbana–Champaign. In particular, we would like to thank our colleagues and collaborators from GSK, including Dr. Steve Hood and Dr. Aneesh Alex, for their inspiration and support of using advanced optical imaging in the pharmaceutical industry. We would also like to thank Rishyashring Raman Iyer, Alexander Ho, and Jindou Shi for their help on figure illustrations and valuable discussion during the preparation of this paper. This work was supported in part by grants from NIH ( R01CA213149 and R01CA241618 ). Additional information can be found at http://biophotonics.illinois.edu .
PY - 2022/12
Y1 - 2022/12
N2 - High-content screening (HCS) and high-throughput screening (HTS) are common processes used in biological research and drug discovery. They allow rapid examination of thousands of compounds tested at the same time for their activity in designed biological assays. After evolving in the 1990s, they quickly became pillars in the pharmaceutical industry, relying on the advances of process automation and adaptation of biochemical assays for small quantities, such as with multiple-well plates. The basic components of HTS and HCS are a miniaturized biological assay, automated transfers and liquid handling steps, and automated quantitative readouts of the assays. However, there has been an increased need for probing complex cellular and subcellular phenotypes as outputs, such as changes in morphology and metabolic activity. The more common approach of labeling is expensive, time-consuming, and prohibits any usage of labeled cells or their products. Novel label-free noninvasive optical imaging could provide tools for multiparametric evaluation at the scale of biopharmaceutical production as well as for personalized medicine.
AB - High-content screening (HCS) and high-throughput screening (HTS) are common processes used in biological research and drug discovery. They allow rapid examination of thousands of compounds tested at the same time for their activity in designed biological assays. After evolving in the 1990s, they quickly became pillars in the pharmaceutical industry, relying on the advances of process automation and adaptation of biochemical assays for small quantities, such as with multiple-well plates. The basic components of HTS and HCS are a miniaturized biological assay, automated transfers and liquid handling steps, and automated quantitative readouts of the assays. However, there has been an increased need for probing complex cellular and subcellular phenotypes as outputs, such as changes in morphology and metabolic activity. The more common approach of labeling is expensive, time-consuming, and prohibits any usage of labeled cells or their products. Novel label-free noninvasive optical imaging could provide tools for multiparametric evaluation at the scale of biopharmaceutical production as well as for personalized medicine.
KW - Biopharmaceuticals
KW - Extracellular vesicles
KW - High-content screening
KW - Label-free optical imaging
UR - http://www.scopus.com/inward/record.url?scp=85139352592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139352592&partnerID=8YFLogxK
U2 - 10.1016/j.cobme.2022.100414
DO - 10.1016/j.cobme.2022.100414
M3 - Review article
AN - SCOPUS:85139352592
SN - 2468-4511
VL - 24
JO - Current Opinion in Biomedical Engineering
JF - Current Opinion in Biomedical Engineering
M1 - 100414
ER -